Overview
Short Course: January 25, 2026 | 8:30AM-12:00PM
Short Course: January 25, 2026 | 1:00-4:30PM
January 26-28, 2026: Conference
Join us for DIA's Global Pharmacovigilance and Risk Management Strategies Conference, the premier event for advancing your expertise in pharmacovigilance and regulatory affairs. Developed in collaboration with regulators and industry experts, this neutral forum provides unparalleled insights into global regulatory harmonization, AI-driven signal detection, and advanced safety analysis tools. At this conference, you’ll hear about updates, opportunities, and challenges shaping the future of drug safety and learn innovative problem-solving strategies that matter most to safety professionals. Attendees will gain actionable knowledge on integrating patient perspectives, optimizing Risk Management Plans (RMPs) and Risk Evaluation and Mitigation Strategies (REMS), and utilizing real-world evidence (RWE) for regulatory submissions and safety monitoring.
This conference also focuses on cutting-edge methodologies for signal detection, benefit-risk assessment, and addressing safety challenges in special populations. An opportunity not to miss to learn best practices for efficient pharmacovigilance operations, including adverse event reporting, outsourcing strategies, and compliance in resource-constrained settings. Register to attend and connect with industry leaders, regulatory authorities, and patient advocates to drive innovation, stay ahead in drug safety, and achieve excellence in regulatory compliance.
Participant Testimonials
My experience at the DIA conference was both enriching and inspiring. It was an incredible opportunity to learn from industry leaders and experts, gaining fresh perspectives on patient safety and pharmacovigilance. The conference provided cutting-edge insights into evolving safety practices, with thought-provoking discussions that not only deepened my understanding but also sparked new ideas.
What stood out the most was the chance to engage in meaningful conversations and networking—connecting with peers, exchanging knowledge, and collaborating on real-world challenges. The energy in the conference rooms, the shared passion for patient safety, and the willingness to tackle complex issues together made the experience truly memorable. Beyond the wealth of information, the conference reinforced the importance of staying ahead in this rapidly evolving field. I walked away feeling more informed, inspired, and connected. I would highly recommend this conference to anyone in pharmacovigilance who wants to learn, grow, and be part of shaping the future of patient safety. – Balmeet Gurm, MD, Executive Director, Therapeutic Area Lead, Patient Safety, Bristol Myers Squibb
These days the events in PV are very commercial focused while this one is the one which industry can learn, connect, and have some thought leader discussions. - Sivakumar Buddha, Safety Manager, Indegene
Getting a chance to make new connections and deepen the existing ones in the PV community are a reason why I particularly like this conference. – Ranjeeta Sinvhal, MD, Executive Medical Director, Medical Safety, AbbVie
Keynote Address Announced!
January 27 | 8:45-9:30AM
Session 1: Keynote Address
Dr. Robert Califf is an Adjunct Professor of Medicine at Duke University and a practicing cardiologist. He served as FDA Commissioner (2016–2017) and Deputy Commissioner for Medical Products and Tobacco. At Duke, he was Vice Chancellor for Clinical and Translational Research and founding director of the Duke Clinical Research Institute. A globally recognized expert in cardiovascular medicine and clinical research, he has over 1,200 peer-reviewed publications. Dr. Califf is a member of the National Academy of Medicine and has served on numerous FDA and NIH advisory boards. He co-founded the Clinical Trials Transformation Initiative and led several national research infrastructure programs.
Featured
Want to learn more about Global Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!
Program Committee
-
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
Bristol Myers Squibb, United States -
Scott Janiczak, PharmD, MPH Team Leader, Division of Pharmacovigilance-I, OSE, CDER
FDA, United States -
Mark Perrott, PhD Managing Partner
Axian Consulting Ltd., United Kingdom -
Bethany Van Veen CEO and Founder
Perspective Pharmacovigilance, United States -
Ranjeeta Sinvhal, MD Executive Medical Director, Medical Safety
AbbVie, United States -
Michael Forstner, PhD, MPH, MSc Managing Director, Head of Pharmacoepidemiology Practice
Mesa Laubela-Consulting, Switzerland -
Balmeet Gurm, MD Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety
Bristol Myers Squibb, United States -
Tarek Hammad, MD, PhD, MS, MSc, FISPE Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV
Takeda Pharmaceuticals, United States -
Stephanie Millican, PhD, MSc Deputy Director Benefit Risk Evaluation, Safety and Surveillance
MHRA, United Kingdom -
Kal Elhoregy, RPh Senior Director, Global Risk Management & Pharmacovigilance Compliance
Amneal Pharmaceuticals, United States -
Jamie Wilkins, PharmD Head, Risk Management Center of Excellence
Pfizer Inc, United States -
Yijing (Hellen) Zhang, MPharm Executive Director, Global Patient Safety
Beigene, China -
Session Chair Invited, BSN, DDS Manager
DIA, Switzerland -
Barbara Hendrickson, DrMed, MD Clinical Associate, Pediatric Infectious Diseases
University of Chicago, United States -
James Buchanan, PharmD President
Covilance LLC, United States
Have an account?